

GENERAL ELECTRIC

NUCLEAR POWER
SYSTEMS DIVISION
MFN 049-83

GENERAL ELECTRIC COMPANY, 175 CURTNER AVE., SAN JOSE, CALIFORNIA 95125
MC 682, (408) 925-5040

March 9, 1983

U.S. Nuclear Regulatory Commission
Office of Nuclear Reactor Regulation
Washington, DC 20555

Attention: Mr. D. G. Eisenhut, Director
Division of Licensing

Gentlemen:

SUBJECT: IN THE MATTER OF 238 NUCLEAR ISLAND
GENERAL ELECTRIC STANDARD SAFETY ANALYSIS REPORT
(GESSAR II) DOCKET NO. STN 50-447

The purpose of this letter is to reaffirm General Electric's request regarding issuance of a Final Design Approval (FDA) for GESSAR II.

After several months of review of this matter with your staff, we have concluded that it is appropriate to issue an FDA in accordance with 10CFR50 Appendix O and with the Nuclear Regulatory Commission's "Statement on Standardization of Nuclear Power Plants", dated August 22, 1978.

In the submittal of GESSAR II which was docketed February 22, 1982, General Electric has a proposed resolution to all of the technical requirements which are currently imposed by the Staff. These include:

- o All current regulatory guides
- o All current regulatory requirements
- o TMI-2 requirements
- o Unresolved Safety Issues
- o Standard Review Plan (NUREG-0800)

In addition to the above, information submitted on the GESSAR II Docket in 1982 addresses the proposed requirements of SECY-82-01 for severe accidents including the CP/ML rule (FR 1/15/82 and 2/1/82).

General Electric reaffirms its request that the NRC issue a Type-2 FDA in May 1983 to be followed by an FDA supplement when the Staff completes its review of GE's severe accident design. This will then be followed by full Nuclear Power Plant Certification pending the outcome of SECY-82-01.

8303150541 830309
PDR ADOCK 05000447
A PDR

E003


GENERAL  ELECTRIC

U.S. Nuclear Regulatory Commission
Page 2

The Type-2 FDA can be issued in accordance with the 1978 Standardization Policy since GESSAR II complies with all regulatory requirements in effect as of the date of docketing for GESSAR II. This would include an effective date for the purposes of applicant referencing for a period of 5 years from the date of the FDA issuance.

I would be pleased to answer any questions on this subject. Please call me at (408) 925-5040 or Rudy Villa on (408) 925-5722.

Very truly yours



Glenn G. Sherwood, Manager
Nuclear Safety and Licensing Operation

GGs:hmm/D030710*

cc: W. J. Dircks
H. R. Denton
R. J. Mattson
V. Stello
C. O. Thomas
F. J. Miraglia